Your browser doesn't support javascript.
loading
Response assessment in paediatric intracranial ependymoma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group.
Lindsay, Holly B; Massimino, Maura; Avula, Shivaram; Stivaros, Stavros; Grundy, Richard; Metrock, Katie; Bhatia, Aashim; Fernández-Teijeiro, Ana; Chiapparini, Luisa; Bennett, Jeffrey; Wright, Karen; Hoffman, Lindsey M; Smith, Amy; Pajtler, Kristian W; Poussaint, Tina Young; Warren, Katherine E; Foreman, Nicholas K; Mirsky, David M.
Afiliação
  • Lindsay HB; Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA. Electronic address: hblindsa@texaschildrens.org.
  • Massimino M; Department of Pediatrics, Fondazione IRCCS Istituto Nazionale dei Tumouri, Milan, Italy.
  • Avula S; Department of Radiology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
  • Stivaros S; Academic Unit of Paediatric Radiology, Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK; Division of Informatics, Imaging, and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester
  • Grundy R; Children's Brain Tumour Research Centre, The Medical School, Queen's Medical Centre, University of Nottingham, Nottingham, UK.
  • Metrock K; Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Bhatia A; Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Fernández-Teijeiro A; Pediatric Onco-Hematology Unit, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Chiapparini L; Neuroradiology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Bennett J; Radiology Ltd, Tucson, AZ, USA.
  • Wright K; Department of Pediatric Oncology, Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
  • Hoffman LM; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ, USA.
  • Smith A; Orlando Health-Arnold Palmer Hospital, Orlando, FL, USA.
  • Pajtler KW; Hopp Children's Cancer Center Heidelberg, Heidelberg, Germany; Division of Pediatric Neurooncology, German Cancer Research Center and German Cancer Consortium, Heidelberg, Germany; Department of Pediatric Oncology, Hematology, and Immunology, Heidelberg University Hospital, Heidelberg, Germany.
  • Poussaint TY; Department of Radiology, Boston Children's Hospital, Boston, MA, USA.
  • Warren KE; Department of Pediatric Oncology, Dana-Farber and Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
  • Foreman NK; The Morgan Adams Foundation Pediatric Brain Tumour Research Program, Department of Pediatrics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, CO, USA.
  • Mirsky DM; Department of Radiology, Children's Hospital Colorado, CO, USA.
Lancet Oncol ; 23(8): e393-e401, 2022 08.
Article em En | MEDLINE | ID: mdl-35901835
ABSTRACT
Response criteria for paediatric intracranial ependymoma vary historically and across different international cooperative groups. The Response Assessment in the Pediatric Neuro-Oncology (RAPNO) working group, consisting of an international panel of paediatric and adult neuro-oncologists, neuro-radiologists, radiation oncologists, and neurosurgeons, was established to address both the issues and the unique challenges in assessing the response in children with CNS tumours. We established a subcommittee to develop response assessment criteria for paediatric ependymoma. Current practice and literature were reviewed to identify major challenges in assessing the response of paediatric ependymoma to clinical trial therapy. For areas in which data were scarce or unavailable, consensus was reached through an iterative process. RAPNO response assessment recommendations include assessing disease response on the basis of changes in tumour volume, and using event-free survival as a study endpoint for patients entering clinical trials without bulky disease. Our recommendations for response assessment include the use of brain and spine MRI, cerebral spinal fluid cytology, neurological examination, and steroid use. Baseline postoperative imaging to assess for residual tumour should be obtained 24-48 h after surgery. Our consensus recommendations and response definitions should be prospectively validated in clinical trials.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias do Sistema Nervoso Central / Ependimoma Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Neoplasias do Sistema Nervoso Central / Ependimoma Tipo de estudo: Guideline / Prognostic_studies Limite: Adult / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article